144 related articles for article (PubMed ID: 8359181)
1. Polymorphic 2-hydroxylation of desipramine. A population and family study.
Dahl ML; Iselius L; Alm C; Svensson JO; Lee D; Johansson I; Ingelman-Sundberg M; Sjöqvist F
Eur J Clin Pharmacol; 1993; 44(5):445-50. PubMed ID: 8359181
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
[TBL] [Abstract][Full Text] [Related]
3. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
[TBL] [Abstract][Full Text] [Related]
4. Phenobarbital induces the 2-hydroxylation of desipramine.
Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
Ther Drug Monit; 1996 Feb; 18(1):60-4. PubMed ID: 8848823
[TBL] [Abstract][Full Text] [Related]
5. Interethnic dissociation between debrisoquine and desipramine hydroxylation.
Rudorfer MV; Lane EA; Potter WZ
J Clin Psychopharmacol; 1985 Apr; 5(2):89-92. PubMed ID: 3988975
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of desipramine metabolism.
Musa MN; Miescke KJ
Int J Clin Pharmacol Ther; 1994 Mar; 32(3):126-30. PubMed ID: 8205373
[TBL] [Abstract][Full Text] [Related]
8. Slow hydroxylation of tricyclic antidepressants--relationship to polymorphic drug oxidation.
Sjöqvist F; Bertilsson L
Prog Clin Biol Res; 1986; 214():169-88. PubMed ID: 3523507
[TBL] [Abstract][Full Text] [Related]
9. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
Du YL; Lou YQ
Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
[TBL] [Abstract][Full Text] [Related]
11. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
Yue QY; Svensson JO; Alm C; Sjöqvist F; Säwe J
Br J Clin Pharmacol; 1989 Dec; 28(6):639-45. PubMed ID: 2611086
[TBL] [Abstract][Full Text] [Related]
12. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
Sanz EJ; Bertilsson L
Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
[TBL] [Abstract][Full Text] [Related]
13. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.
Llerena A; Edman G; Cobaleda J; Benítez J; Schalling D; Bertilsson L
Acta Psychiatr Scand; 1993 Jan; 87(1):23-8. PubMed ID: 8424321
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.
Steiner E; Bertilsson L; Säwe J; Bertling I; Sjöqvist F
Clin Pharmacol Ther; 1988 Oct; 44(4):431-5. PubMed ID: 3168394
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A; Dorado P; Peñas-Lledó EM
Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
[TBL] [Abstract][Full Text] [Related]
16. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
Kallio J; Lindberg R; Huupponen R; Iisalo E
Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
[TBL] [Abstract][Full Text] [Related]
17. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
[TBL] [Abstract][Full Text] [Related]
18. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.
Steiner E; Iselius L; Alván G; Lindsten J; Sjöqvist F
Clin Pharmacol Ther; 1985 Oct; 38(4):394-401. PubMed ID: 4042522
[TBL] [Abstract][Full Text] [Related]
19. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
Nichols AI; Abell M; Chen Y; Behrle JA; Frick G; Paul J
Int Clin Psychopharmacol; 2013 Mar; 28(2):99-105. PubMed ID: 23221858
[TBL] [Abstract][Full Text] [Related]
20. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
LLerena A; Berecz R; de la Rubia A; Fernández-Salguero P; Dorado P
Ther Drug Monit; 2001 Dec; 23(6):616-20. PubMed ID: 11802093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
